EDSAHealthcare · BiotechnologyThe 2 Wall Street analysts covering Edesa Biotech, Inc. hold a median 12-month price target of $19 — +323.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Edesa Biotech, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (83): Smaller than most of the companies we track.
Growth (17): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on EDSA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +323.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | $5.00 |
| 27 June 2025 | HC Wainwright & Co. | Assumes | Buy | $5.00 |
| 13 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | $21 |
| 28 June 2024 | HC Wainwright & Co. | Reiterates | Buy | $21 |
| 14 Feb 2024 | HC Wainwright & Co. | Reiterates | Buy | $21 |
| 29 Nov 2023 | HC Wainwright & Co. | Maintains | Buy | $70 → $21 |
| 22 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | $10 |
| 12 Oct 2023 | Brookline Capital | Maintains | Buy | $57 |
| 15 Aug 2023 | HC Wainwright & Co. | Maintains | Buy | $16 → $10 |
| 24 May 2023 | HC Wainwright & Co. | Reiterates | Buy | $16 |
| 15 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | $16 |
| 14 Feb 2023 | HC Wainwright & Co. | Reiterates | Buy | $16 |
| 20 Dec 2021 | HC Wainwright & Co. | Initiates | Buy | $16 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EDSA appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 88% of US stocks
Cheaper than 1% of US stocks
Cheaper than 74% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 11% of US stocks
Higher than 5% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Edesa Biotech, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Edesa Biotech announced the pricing of a $25.0 million underwritten public offering of common shares, pre-funded warrants, and accompanying common share warrants. The offering includes an underwriters' 30-day option to purchase additional shares and warrants.
Why it matters — The offering provides Edesa with approximately $25.0 million in gross proceeds to fund its clinical-stage operations.
Edesa Biotech announced it has commenced an underwritten public offering of its common shares (or pre-funded warrants in lieu thereof) and accompanying common share warrants. The company also expects to grant underwriters a 30-day option to purchase up to 15% more shares and warrants; the offering is subject to market and other conditions with no assurance of completion, size, or terms.
Why it matters — A proposed public offering could affect Edesa's share structure and capital position, so investors tracking EDSA will watch for details on the offering's size and terms.
Edesa Biotech reported financial results for the fiscal third quarter and nine months ended June 30, 2026, and provided a business update. The company focuses on developing host-directed therapeutics for immuno-inflammatory diseases.
Why it matters — The quarterly report offers EDSA watchers a routine update on the company's financial position and operational progress.
The 2 Wall Street analysts covering Edesa Biotech, Inc. have a median 12-month price target of $19, with estimates ranging from $9 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering Edesa Biotech, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Edesa Biotech, Inc. 58 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Edesa Biotech, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (83 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +323.2% from the last close, and Ticker Nerd's factor model ranks Edesa Biotech, Inc. 58 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Edesa Biotech, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EDSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $21 over the next 12 months.
Edesa Biotech, Inc. returned +88.7% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Edesa Biotech Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of innovative therapies for dermatological and gastrointestinal indications.
The most recent item we track (GlobeNewsWire, 20 Aug 2026): "Edesa Biotech Announces Pricing of $25.0 Million Public Offering". Edesa Biotech announced the pricing of a $25.0 million underwritten public offering of common shares, pre-funded warrants, and accompanying common share warrants. The offering includes an underwriters' 30-day option to purchase additional shares and warrants.
Edesa Biotech Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of innovative therapies for dermatological and gastrointestinal indications. The company's primary purpose is to address unmet medical needs by leveraging its proprietary research and extensive clinical expertise to create novel treatment options. Edesa Biotech Inc. specializes in small molecule drugs and biologics, targeting conditions where existing therapies are inadequate or non-existent. Notably, the company's pipeline includes potential treatments for atopic dermatitis and allergic contact dermatitis, aiming to improve patient outcomes in skin health. Situated in a competitive biotech industry, Edesa Biotech plays a significant role by contributing to medical advancement and potential breakthrough treatments in dermatology. Through its dedication to clinical trials and regulatory approvals, Edesa Biotech strives to enhance its market position and impact healthcare practices worldwide.
CEO Dr. Pardeep Nijhawan FRCPC, M.D. · 17 employees · Canada · https://www.edesabiotech.com